News

Inebilizumab will be developed and marketed in the Asian regions for the treatment of neuromyelitis optica spectrum disorder (NMOSD), and also other potential indications in the future. As

Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with very high affinity, specifically preventing the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling, thereby

The acquisition of Amarex will help NSF to expand its consulting services to the medical device and pharma/biotech industries. Amarex will be included in NSF’s global health science

IDEAYA previously announced initiation of this Phase 1/2 clinical trial evaluating IDE196 in a tissue-type agnostic basket trial for treatment of metastatic uveal melanoma and other solid tumors

The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. There were two phases with the

Under the terms of the worldwide exclusive licensing agreement, Pfizer will pay an upfront license fee of $250m to Akcea and Ionis. The fee will be split equally

Beovu, which is also known as RTH258, is now the first anti-VEGF to be approved by the regulator. According to Novartis, the drug can offer greater fluid resolution

The regulator approved the new drug application (NDA) for PF708, which was submitted under the 505(b)(2) regulatory pathway with Eli Lilly and Company’s Forteo as the reference medicine.

The approval is supported by data from the Phase III GRECO trial and the Phase I AMES trial, which achieved their primary objective of usability and pharmacokinetic (PK)